Drug
Tuvusertib clinical trials
Also written M1774.
- studies test it
- 11
- open now
- 6
- in phase 3
- 0
- first study started
- 2023
Keep track of what changes. Save the tuvusertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- M1774
- 13
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 8
National Cancer Institute (NCI) (4) · EMD Serono Research & Development Institute, Inc. (2) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Institut Paoli-Calmettes (1) · Grupo Español de Investigación en Neurooncología (1) · Panagiotis Konstantinopoulos, MD, PhD (1) · Institut Curie (1)
Often tested with
Tested in the same studies.
Avelumab (2) · Cemiplimab (1) · Fulvestrant (1) · ZEN-3694 (1) · Peposertib (1) · Temozolomide (1) · DFP-13318 (1) · Pegylated SN-38 Conjugate PLX038 (1)
Studies
Open first, then newest update. How each study uses tuvusertib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05950464Written as Tuvusertib
- Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT05687136Written as Tuvusertib
- Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessRecruitingPhase 1/2National Cancer Institute (NCI)NCT05691491Written as Tuvusertib
- Tuvusertib in Astrocytoma With ATRX MutationRecruitingPhase 2Grupo Español de Investigación en NeurooncologíaNCT07417761Written as Tuvusertib
- Avelumab and M1774 in ARID1A-mutated Endometrial CancerRecruitingPhase 2Panagiotis Konstantinopoulos, MD, PhDNCT06518564Written as M1774
- I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast CancersNot yet recruitingPhase 1/2Institut Paoli-CalmettesNCT05986071Written as M1774
- Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedPhase 1/2EMD Serono Research & Development Institute, Inc.NCT05882734Written as M1774
- Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05828082Written as Tuvusertib
- Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)CompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT06308263Written as Tuvusertib [14C]Tuvusertib microtracer
- A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid TumorsTerminatedPhase 1Institut CurieNCT06337630Written as PLX038 + Tuvusertib
- Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)WithdrawnPhase 2EMD Serono Research & Development Institute, Inc.NCT06424717Written as Tuvusertib
Given in every arm · 5 — tuvusertib is usual care beside what is tested
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT06433219Written as Tuvusertib (M1774)
- Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT05396833Written as Tuvusertib
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingPhase 1EMD Serono Research & Development Institute, Inc.NCT06421935Written as Tuvusertib
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Active, not recruitingPhase 1EMD Serono Research & Development Institute, Inc.NCT04170153Written as M1774
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05947500Written as Tuvusertib
Codes
What other systems call tuvusertib · ClinicalTrials.gg INT016942
- UNII (FDA) JE1BE6ZGZ7TUVUSERTIBOne source FDA
- NCI Thesaurus C171067TuvusertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JE1BE6ZGZ7 | TUVUSERTIB | One source FDA |
| NCI Thesaurus | C171067 | Tuvusertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.